Daniel Hood, MD
Neurology · Battle Creek, MINPI 1639127970
Payments from drug & device makers
Across 177 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$643
- AstraZeneca$563
- Novartis$477
- EMD Serono, Inc.$415
- Biogen$354
- Medtronic$341
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$210%
- Travel & lodging$1493%
- Food & beverage$4,70996%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 39 | $643 |
| AstraZeneca | 7 | $563 |
| Novartis | 19 | $477 |
| EMD Serono, Inc. | 13 | $415 |
| Biogen | 11 | $354 |
| Medtronic | 4 | $341 |
| Eisai Inc. | 11 | $331 |
| Insightec,inc | 2 | $182 |
| Lilly USA, LLC | 6 | $122 |
| Bristol Myers Squibb | 6 | $119 |
| Jazz Pharmaceuticals Inc. | 1 | $107 |
| Acadia Pharmaceuticals Inc | 6 | $107 |
| Pfizer | 6 | $106 |
| Biohaven Pharmaceuticals, Inc. | 4 | $99 |
| E.r. Squibb & Sons, L.L.C. | 1 | $91 |
| Abbott | 3 | $88 |
| UCB, Inc. | 5 | $86 |
| Genentech USA, Inc. | 6 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $56 |
| Argenx US, Inc. | 3 | $53 |
| Neurelis, Inc. | 3 | $51 |
| Sanofi | 1 | $47 |
| TG Therapeutics, Inc. | 2 | $45 |
| Greenwich Biosciences, Inc. | 1 | $42 |
| Supernus Pharmaceuticals, Inc. | 3 | $40 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Genentech, Inc. | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Johnson & Johnson | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $30 |
| Lundbeck LLC | 1 | $29 |
| SK Life Science, Inc. | 1 | $28 |
| Acorda Therapeutics, Inc | 1 | $21 |
| CSL Behring | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,911 in reported general payments places this provider in the 65th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $397,034 |
| RebifInterferon Beta-1a/Albumin | 26 | $286,698 |
| Kesimpta PenOfatumumab | 18 | $251,675 |
| Austedo XrDeutetrabenazine | 19 | $166,090 |
| CopaxoneGlatiramer Acetate | 22 | $120,709 |
| AubagioTeriflunomide | 11 | $101,155 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $98,902 |
| Teriflunomide | 46 | $53,475 |
| AmpyraDalfampridine | 11 | $47,667 |
| Nurtec OdtRimegepant Sulfate | 43 | $44,887 |
| Dalfampridine ErDalfampridine | 87 | $41,953 |
| LamictalLamotrigine | 19 | $33,604 |
| Tetrabenazine | 12 | $30,450 |
| Dimethyl Fumarate | 36 | $23,792 |
| QuliptaAtogepant | 22 | $23,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $31 | $397,03416 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Copaxone | $643 | $286,79941 claims |
| EMD Serono, Inc.Rebif | $415 | $286,69826 claims |
| SanofiAubagio | $47 | $101,15511 claims |
| PfizerNurtec Odt, Dilantin | $106 | $51,78889 claims |
| Acorda Therapeutics, IncAmpyra | $21 | $47,66711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 652 neurology providers in Michigan.
Other neurology in Battle Creek
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
- Jeanie CoteOwosso$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.